# US 2025/0084419 A1 · Treatment Of Acne Rosacea With Pancreatic Lipase-Related Protein 3 (PNLIPRP3) Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084419 A1
- Document ID: US20250084419A1
- Status: Published application
- Kind: A1
- Application number: 18/830,786
- Filed: 2024-09-11
- Published: 2025-03-13
- Earliest claimed: 2023-09-12
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Antoine Baldassari; William Palmer; Katherine Siminovitch; Manuel Ferreira; Priyanka Nakka; Aris Baras
- Web page: https://patentgrep.com/patent/US20250084419A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/156: Polymorphic or mutational markers
- C12Y 301/03001: Alkaline phosphatase (3.1.3.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

The present disclosure generally relates to the treatment of subjects having acne rosacea or at risk of developing acne rosacea by administering a Pancreatic Lipase-Related Protein 3 (PNLIPRP3) inhibitor to the subject.

## Claims

### Claim 1

A method of treating a subject having acne rosacea or at risk of developing acne rosacea, the method comprising administering a Pancreatic Lipase-Related Protein 3 (PNLIPRP3) inhibitor to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PNLIPRP3 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to a PNLIPRP3 nucleic acid molecule.

### Claim 3 (depends on 2)

The method of claim 2, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), and/or a short hairpin RNA (shRNA).

### Claim 4 (depends on 3)

The method of claim 3, wherein the inhibitory nucleic acid molecule comprises an siRNA.

### Claim 5 (depends on 3)

The method of claim 3, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is also administered an acne rosacea therapeutic agent or acne rosacea therapy.

### Claim 7 (depends on 1)

The method of claim 1, further comprising detecting the presence or absence of a PNLIPRP3 variant nucleic acid molecule in a biological sample from the subject.

### Claim 8 (depends on 7)

The method of claim 7, further comprising administering an acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy to the subject when the PNLIPRP3 variant nucleic acid molecule is absent from the biological sample.

### Claim 9 (depends on 7)

The method of claim 7, further comprising administering an acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy to the subject when the subject is heterozygous for the PNLIPRP3 variant nucleic acid molecule.

### Claim 10 (depends on 7)

The method of claim 7, wherein the PNLIPRP3 variant nucleic acid molecule comprises a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, a missense variant, an in-frame indel variant, and/or a variant that encodes a truncated PNLIPRP3 variant polypeptide.

### Claim 11 (depends on 7)

The method of claim 7, wherein the PNLIPRP3 variant nucleic acid molecule comprises the genetic variation 10:116455798:G:GA (rs145843135).

### Claim 12

A method of treating a subject having acne rosacea or at risk of developing acne rosacea by administering an acne rosacea therapeutic agent or acne rosacea therapy, the method comprising:
determining or having determined whether the subject has a Pancreatic Lipase-Related Protein 3 (PNLIPRP3) variant nucleic acid molecule, by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising a PNLIPRP3 variant nucleic acid molecule; and
administering or continuing to administer the acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy, and/or a PNLIPRP3 inhibitor to a subject that is PNLIPRP3 reference;
administering or continuing to administer the acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy, and/or a PNLIPRP3 inhibitor to a subject that is heterozygous for the PNLIPRP3 variant nucleic acid molecule; or
administering or continuing to administer the acne rosacea therapeutic agent in a standard dosage amount or acne rosacea therapy to a subject that is homozygous for the PNLIPRP3 variant nucleic acid molecule;
wherein the presence of the PNLIPRP3 variant nucleic acid molecule indicates the subject has a decreased risk of developing acne rosacea.

### Claim 13 (depends on 12)

The method of claim 12, wherein the PNLIPRP3 inhibitor comprises an inhibitory nucleic acid molecule that hybridizes to a PNLIPRP3 nucleic acid molecule.

### Claim 14 (depends on 13)

The method of claim 13, wherein the inhibitory nucleic acid molecule comprises an antisense nucleic acid molecule, a small interfering RNA (siRNA), and/or a short hairpin RNA (shRNA).

### Claim 15 (depends on 13)

The method of claim 13, wherein the inhibitory nucleic acid molecule comprises an siRNA.

### Claim 16

(canceled)

### Claim 17 (depends on 12)

The method of claim 12, wherein the subject is heterozygous for the PNLIPRP3 variant nucleic acid molecule, and the subject is administered or continued to be administered the acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy and the PNLIPRP3 inhibitor.

### Claim 18 (depends on 12)

The method of claim 12, wherein the subject is PNLIPRP3 reference, and the subject is administered or continued to be administered the acne rosacea therapeutic agent in an amount that is the same as or less than a standard dosage amount or acne rosacea therapy and the PNLIPRP3 inhibitor.

### Claim 19 (depends on 12)

The method of claim 12, wherein the PNLIPRP3 variant nucleic acid molecule comprises a splice-site variant, a stop-gain variant, a start-loss variant, a stop-loss variant, a frameshift variant, a missense variant, an in-frame indel variant, and/or a variant that encodes a truncated PNLIPRP3 variant polypeptide.

### Claim 20 (depends on 12)

The method of claim 12, wherein the PNLIPRP3 variant nucleic acid molecule comprises the genetic variation 10:116455798:G:GA (rs145843135).

### Claim 21

A method of identifying a subject having an increased risk of developing acne rosacea, the method comprising:
determining or having determined the presence or absence of a PNLIPRP3 variant nucleic acid molecule in a biological sample obtained from the subject;
wherein:
when the subject is PNLIPRP3 reference, then the subject has an increased risk of developing acne rosacea; and
when the subject is heterozygous or homozygous for the PNLIPRP3 variant nucleic acid molecule, then the subject has a decreased risk of developing acne rosacea.

### Claim at position 22

22-41. (canceled)
